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Received March 1, 2015; accepted December 10, 2015AbstractBackground: Trimethoprim/sulfamethoxazole (TMP/SMX) is currently the most effective therapeutic agent for Pneumocystis jirovecii pneu-
monia (PJP) in patients with AIDS. The major drawback is the frequent occurrence of adverse reactions (ADRs).The current study was designed
to determine the frequency and risk factors for TMP/SMX-related ADRs among patients with PJP and AIDS.
Methods: A retrospective study was conducted in adult patients with PJP and AIDS who were admitted to the Veterans General Hospital in,
Kaohsiung, Taiwan between January 2006 and December 2011. Charts were reviewed to determine the effect of age, risk behaviors, severity of
illness, viral load, CD4 cell counts, use of corticosteroids, and dosage and duration of TMP/SMX on ADRs during hospitalization. Patients who
received TMP/SMX for  5 days or with an incomplete medical record were excluded. Multivariate logistic regression was used to calculate the
hazard ratio (HR) for ADRs.
Results: Fifty two of 75 patients with PJP and AIDS met the study criteria. Of these patients, 21/52 (40.3%) developed an ADR. Among the 21
patients who suffered an ADR, skin rash was noted in 10 (47.6%), liver function impairment in nine (42.9%), elevated creatinine in eight (38.1%),
fever in four (19%), and gastrointestinal symptoms in three (14.3%). Most of the ADRs occurred within the 1st 2 weeks of TMP/SMX therapy. Cox
proportional hazards analysis revealed that a daily dose of TMP/SMXof 16mg/kg (HR, 3.8; 95% confidence interval, 1.40e10.35; p¼ 0.009) and
age 34 years (HR, 4.30; 95% confidence interval, 1.52e12.14; p ¼ 0.006) were independently associated with ADRs.
Conclusion: We found a high incidence of ADRs among patients with PJP and AIDS treated with TMP/SMX, and most involved the skin and
liver. A daily dose of  16 mg/kg of TMP/SMX and age 34 years were independent risk factors for ADRs.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Pneumocystis jiroveci pneumonia (PJP) is a major cause of
morbidity and mortality among immunocompromised pa-
tients. It continues to be a common early manifestation of
AIDS.1 The recommended treatment for PJP has been un-
changed for many years.2 Trimethoprim/sulfamethoxazolesevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
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prophylaxis of PJP in patients with AIDS. TMP/SMX has the
advantages of good tissue penetration and the bioavailability
of the oral form is comparable to parenteral administration. It
provides the most rapid clinical response among the current
antipneumocystis agents. Although highly effective, the use of
TMP/SMX for patients with AIDS is limited by the high
frequency of adverse reactions (ADRs) ranging from 29% to
65%.3e5 By contrast, ADRs are reported to occur in less than
10% of the general population and in immunocompetent pa-
tients treated with TMP/SMX.6
The risk factor for ADRs to TMP/SMX remains poorly
understood. Carr et al7 reported hypersensitivity to TMP/SMX
in 39/143 (27%) of AIDS patients with PJP. They found that a
CD4:CD8 ratio of > 0.1 and treatment for < 14 days were
independent predictive factors for hypersensitivity. Veenstra
et al8 found that a low CD4 cell count at baseline and the use
of antiretroviral therapy, before starting TMP/SMX prophy-
laxis for human immunodeficiency virus (HIV) infected pa-
tients, were predictors of ADRs to TMP/SMX. The current
study was designed to determine whether the daily dose of
TMP/SMX based on body weight might be an independent
risk factor for ADRs in AIDS patients treated for PJP. It was
based on our clinical observation that TMP/SMX-related
ADRs appeared to occur more often among lower-weight
patients receiving a standard dose of TMP/SMX.
2. Methods2.1. Ethical statementsThis study was approved by the Institutional Review Board
of the Kaohsiung Veterans General Hospital, Kaohsiung,
Taiwan. The study complied with all ethical considerations
involving human participants. All of the data was decoded and
the patient's informed consent was not mandatory.2.2. Study populationsWe conducted a retrospective chart review of all adult pa-
tients treated for PJP at the Kaohsiung Veterans General
Hospital between January 2006 and December 2011. Patients
were included in the analysis if they were treated with TMP/
SMX for a first episode of PJP, had not received TMP/SMX
previously for PJP prophylaxis, and had no prior history of
ADRs to TMP/SMX. Patients were excluded if they were
younger than 18 years, had received TMP/SMX for  5 days,
or the records were incomplete. The diagnosis of PJP was
based on cytology, histopathology, or polymerase chain reac-
tion assay of respiratory specimens or typical radiological
findings of interstitial pneumonitis in patients with AIDS.22.3. Data collectionA standardized case record form was used to collect the
demographic and comorbid characteristics of the population,
laboratory findings (hemogram, electrolytes, serum creatinine,and hepatic profile), mode of diagnosis of PJP, radiologic
findings, body weight, height and body mass index, dosage of
TMP/SMX, use of adjunctive steroids, and in-hospital mor-
tality. The HIV-related variables included sexual behavior,
CD4 cell count, plasma HIV RNA load, and current antire-
troviral therapy. An ADR record form was used to identify
ADRs according to the involved organ systems. The Naranjo
score which was used to estimate the probability of a temporal
relationship between the drug and an ADR. A score of > 8 was
considered to be definite, 5e8 probable, 1e4 possible, and < 1
doubtful.9 The preventability of an ADR was evaluated using
the criteria developed by Schumock and Thornton.10
The initial daily dose of TMP/SMX was based on a visual
estimate of body weight by the attending physician and admin-
istered by the oral or intravenous route every 6e8 hours. We
recalculated the dosage based on the body weight on admission.2.4. Criteria for TMP/SMX-related ADRsA potential adverse reaction was suspected when treatment
with TMP/SMXwas discontinued or the dosewas changed prior
to the completion of therapy. The physicians' notes were
reviewed to determine the reason for the change as drug failure,
a potential ADR, or other reasons. We excluded laboratory or
clinical abnormalities that could have been caused by an un-
derlying disease, or another drug (such as aminoglycoside
nephrotoxicity). The total daily dose of TMP/SMX was recor-
ded by body weight and the number of days treated before being
stopped. Cutaneous reactions were defined as the development
of a rash with or without fever or pruritus. Gastrointestinal
symptoms were defined as the occurrence of nausea, vomiting,
dyspepsia, or diarrhea. Hepatitis was defined as alanine trans-
aminase or alkaline phosphatase two or more times normal or
with two-fold or more increase. Elevated creatinine was defined
as 1.5 mg/dL, or a 30% increase. Pancytopenia was defined
as anemia with hemoglobin < 12 g/dL combined with leuko-
penia (leukocyte count < 4000/mL or with a  1000/mL
decrease) and thrombocytopenia (platelet count< 150 103/mL
or with 30 103/mL decrease). Lactic acidosis was defined as
serum lactate level> 2.1 mmol/L. Hyperkalemia was defined as
serum potassium level > 5 mmol/L. The diagnosis of acute
psychosis was based on the diagnostic criteria for substance-
induced psychotic disorder as defined in the Diagnostic and
Statistical Manual ofMental Disorders, 4th edition, text revision
(DSM-IV-TR).112.5. TreatmentThe standard initial recommended treatment for PJP at our
hospital is TMP/SMX at a dose of 15e20mg/kg/d for 21 days to
all patients except those with a history of sulfonamide hyper-
sensitivity. The actual dosagewas at the discretion of the treating
physicians. This led to instances of under- or overdosing TMP/
SMXbecause most physicians based the dose on estimated body
weight. Prednisolone was administered at a dose of 40 mg twice
daily for 5 days, 40 mg daily for 5 days, and 20 mg daily for
11 days for patients with severe hypoxemia.2
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(version 20.0; SPSS Inc., Chicago, IL, USA).All continuous
variables were expressed as medians and differences between
groups were analyzed using the ManneWhitney U test. The
categorical variables were expressed as percentages and
numbers. Pearson's Chi-square test or Fisher's exact test was
used to analyze correlations between variables. KaplaneMeier
curves were estimated to determine the association between
adverse drug and dosage of TMP/SMX. A Cox proportional
analysis was used to calculate hazards ratios for ADRs. All
explanatory variables with a p value < 0.5 in the univariate
analyses were eligible to enter the multivariate Cox propor-
tional hazards model with the backward elimination method
and considered to be significant when p < 0.05.
3. Results
Seventy-five patients were treated with TMP/SMX for
presumed PJP and AIDS from January 2006 to December
2011. Twenty-three were excluded for the reasons shown in
Fig. 1, and the remaining 52 patients were eligible for detailed
analysis. Twenty-one of the 52 patients (40.3%) developed one
or more ADRs attributable to TMP/SMX. The baseline char-
acteristics of the patient population according to whether they
had a TMP/SMX-related ADR are shown in Table 1.There
were no significant differences between the groups in survival,
risk behaviors, HIV-1 markers, serum creatinine, or dose of
corticosteroids. The only significant difference between the
groups was the median daily dose of TMP/SMX; 16.5 mg/kg
body weight for patients with an ADR versus 14.7 mg/kg body
weight for those without an ADR, p < 0.036.
The frequency, median time, and range of onset for each
ADR, following the initial dose of TMP/SMX, are shown in
Table 2. Among the 21 patients who suffered an ADR, skin
rash was noted in 10 (47.6%), liver function impairment inFig. 1. Flow chart of the study population according to entry criteria.nine (42.9%), elevated creatinine in eight (38.1%), fever in
four (19%), and gastrointestinal symptoms in three (14.3%), as
noted in Table 2. The combination antiretroviral therapy
(cART) regimens included PI/r in 16 (30.7%) of the 52 pa-
tients; NNRTI in 27 (51.9%) of the patients, which consisted
of nevirapine (37%), efavirenz (63%), whereas nine (17.3%)
of the patients were not prescribed cART. Only five of the 52
patients (9.6%) concomitantly used cART and TMP/SMX.
The likelihood that the adverse event was associated with the
antiretroviral agent was excluded by the physician in all of the
five patients. Most of the ADRS occurred within the 1st
2 weeks of TMP/SMX therapy. The median time of onset for
any ADR was 12 days (range, 1e25 days). The median time to
onset of gastrointestinal symptoms was significantly shorter
(median 5 days) than other adverse effects (median 12 days),
p ¼ 0.02. Assessment by the Naranjo score revealed that
81.6% of the ADRs could be categorized as “probable” (scores
ranged from 5 to 8), while 18.4% of the ADRs were catego-
rized as “possible” (score ranged from 1 one 4). Assessment of
the preventability of an ADR, based on the modified Schu-
mock and Thornton10 scale revealed that most of the ADRs
were “not preventable”. Nausea, vomiting, and gastrointestinal
symptoms were considered to be “definitely preventable”.
Seventeen of the 21 patients (80.9%) fully recovered after
adjustment of the dose or a change to another form of therapy.
These included switching TMP/SMX to primaquine plus
clindamycin in eight patients (38.1%), reducing the dose in
nine patients (42.9%), discontinuing TMP/SMX in two pa-
tients (9.5%), and continuing the same dose of TMP/SMX
together with a medication that relieved the ADR in two pa-
tients (9.5%).
Univariate analysis revealed no significant differences be-
tween patients who did or did not develop an ADR in relation
to body mass index, hematological findings, intravenous and
oral forms of TMP/SMX, and CD4 cell count. A Cox pro-
portional analysis revealed that a greater daily dose of TMP/
SMX and age were independent factors for ADRs (Table 3).
To further explore the relationship between the dosage of
TMP/SMX and the occurrence of ADRs over time, we divided
the patient population into those who received a daily dose of
 16 mg/kg and  15mg/kg. The KaplaneMeier curve is
shown in Fig. 2.
4. Discussion
TMP/SMX remains the drug of choice for the treatment and
prophylaxis of PJP in patients with AIDS, but its use is limited
by the high incidence of hypersensitivity reactions and other
ADRs.3e5 The frequency is estimated to be 29e65%.7 In the
current retrospective study, we found that 40.3% of our pa-
tients developed an adverse reaction to TMP/SMX. Most
occurred within 2 weeks following the initial dose. We sus-
pected that higher daily doses might be responsible when we
noted that physicians at our hospital often estimated body
weight based on visual inspection rather than by actual weight.
After adjustment for demographic, clinical, and laboratory risk
Table 1
Baseline characteristics of AIDS patients with and without ADRs to TMP/SMX.
Variable Patients with
ADRs (n ¼ 21)
Patients without
ADRs (n ¼ 31)
p
Age (y) 34 (22e66) 35 (20e59) 0.993
Survival 17 (81) 24 (77.4) 0.762
Male 21 (100) 29 (93.5) 0.24
Exposure 0.251
Homosexual 15 (48.4)
Heterosexual 6 (19.4)
Bisexual 1 (3.2)
Unknown 9 (29)
BMI (kg/m2) 19.83 (15.24e26.45) 20.95 (15.43e27.4) 0.198
Newly HIV diagnosed 19 (90.5) 19 (61.3) 0.489
12 tablets daily of TMP/SMX 15 (28.8) 23 (44.2) 0.535
Daily dose of TMP (mg/kg) 16.5 (11.21e21.33) 14.7 (7.38e19.2) 0.036
15 mg/kg of TMP 14 (28) 13 (26) 0.13
IV form 7 (33.3) 11 (35.5) 0.874
WBC (1000/cumm) 6.83 (4.63e10.9) 5.6 (2.97e13.59) 0.189
Hgb (%) 12.2 (10.2e16) 11.6 (6.4e14.8) 0.271
Lym (%) 13 (5e31) 18 (0e40) 0.327
LDH (U/L) 354 (132e964) 432 (167e665) 0.947
Serum creatinine (mg/dL) 0.98 ± 0.2 0.93 ± 0.22 0.4
Latest plasma HIV RNA load, patients with data 21 (100) 27 (87)
5 log copies/mL 17 (81) 24 (89) 0.77
CD4þ count (cells/mL) 18 (2e90) 21 (0e151) 0.765
Standard steroid dose (equivalent to prednisone) 11 (21.1) 21 (40.3) 0.24
ART-regimen
PI þ NRTI 4 (7.5) 5 (9.5)
Kaletra þ kivexa 2 (3.7) 5 (9.5)
NRTI þ NNRTI 1 (1.7) 2 (3.7)
NVP þ kivexa 3 (5.7) 6 (11.5)
EFV þ kivexa 4 (7.5) 4 (7.5)
EFV þ combivir 4 (7.5) 3 (7.5)
No ART prescribed 3 (5.7) 6 (11.5)
Data are presented as n (%),median (range), or mean ± standard deviation.
ADR ¼ adverse drug reaction; ART ¼ antiretroviral therapy; BMI ¼ body mass index; EFV ¼ efavirenz; HIV ¼ human immunodeficiency virus;
Hgb ¼ hemoglobin; LDH ¼ lactate dehydrogenase; Lym ¼ lymphocytes; NNRTI ¼ nonnucleoside reverse-transcriptase inhibitor; NRTI ¼ nucleoside reverse
transcriptase inhibitor; NVP ¼ nevirapine; PI ¼ protease inhibitor; TMP/SMX ¼ trimethoprim/sulfamethoxazole; WBC ¼ white blood cells.
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higher daily doses of TMP/SMX based on body weight.
Several explanations have been offered for the association
between TMP/SMX and ADRs among patients with PNP and
AIDS. In a review of the literature, Carr et al7 noted that
suggested causes included the degree of immunodeficiency,
longer duration, and higher dose of TMP/SMX therapy,Table 2
Frequency of each adverse drug reaction (ADR) to trimethoprim/sulfameth-
oxazole among 21 AIDS patients with Pneumocystis jirovecii pneumonia.
Frequency
n (%)
Onset of ADR (d)
Median (range)
Cutaneous 10 (47.6) 12 (2e20)
Gastrointestinal 3 (14.3) 5 (1e12)
Liver dysfunction 9 (42.9) 12 (10e25)
Renal dysfunction 8 (38.1) 13 (5e22)
Fever 4 (19) 12 (12e13)
Pancytopenia 1 (4.8) 21
Lactate acidosis 1 (4.8) 8
Acute psychosis 1 (4.8) 10coexisting cytomegalovirus, or EpsteineBarr virus infection,
slow acetylator phenotype, rate of HIV replication, atopic
diathesis, and glutathione deficiency. In a retrospective study,
they found that hypersensitivity reactions, defined as a cuta-
neous morbilliform eruption, occurred in 39 (27%) of 143
patients. On regression analysis they found that a CD4:CD8
ratio of > 0.10 and treatment for < 14 days were indepen-
dently predictive of hypersensitivity. Use of corticosteroids
tended to reduce the frequency of reactions. They postulated
that T lymphocytes may be important in the pathogenesis of
these reactions. They did not consider whether there was a
relationship between the dose of TMP/SMX and onset of
rash.7 Lee et al12 found that a higher daily dose of TMP/SMX
and use of adjunctive steroids were associated with acute
psychosis. The incidence increased from none in 16 patients
who received a daily TMP dose of < 12 mg/kg to 23.5% (4/17)
in those who received a daily dose of > 18 mg/kg. They did
not note the occurrence of other TMP/SMX-associated ADRs.
Hughes et al13 reported that the incidence of anemia, neu-
tropenia, and azotemia increased with increasing trimethoprim
plasma concentration, while other adverse events
Fig. 2. KaplaneMeier curve estimating the probability of an adverse
drug reaction to trimethoprim/sulfamethoxazole according to a daily dose
of 16 mg/kg is shown by the solid line and 15mg/kg is shown by the dotted
line.
Table 3
Hazard ratio for adverse reactions to trimethoprim/sulfamethoxazole in
patients with pneumocystis pneumonia and AIDS.
Risk factor Unadjusted Adjusted
Hazard ratio
(95% CI)
p Hazard ratio
(95% CI)
p
Age (y)
34 0.00 0.00
35 3.83 (1.25e11.77) 0.019 4.30 (1.52e12.14) 0.006
Exposure
MSM 0.00 0.00
Heterosexual/
other/unknown
0.9 (0.27e2.98) 0.9 0.9 (0.27e2.98) 0.86
WBC (1000/cumm) 0.97 (0.71e1.33) 0.842 0.97 (0.71e1.33) 0.86
CD4þ count (cells/mL)
49 0.00 0.00
50 0.65 (0.14e3.00) 0.58 0.67 (0.19e2.38) 0.53
Steroid
No 0.00 0.00
Yes 1.27 (0.29e5.45) 0.75 1.35 (0.52e3.48) 0.54
Daily dose of TMP
(mg/kg)
15 0.00 0.00
16 4.11 (1.26e13.42) 0.019 3.80 (1.40e10.35) 0.009
CI ¼ confidence interval; MSM ¼ men who have sex with men;
TMP ¼ trimethoprim; WBC ¼ white blood cells.
318 H.-M. Chang et al. / Journal of the Chinese Medical Association 79 (2016) 314e319(gastrointestinal disorders, rash, fever, and liver function ab-
normalities) were independent of plasma concentration.
Serum creatinine has been shown to rise in a dose-related
manner in patients treated with trimethoprim. It is caused by
a decrease in tubular secretion of creatinine associated with a
slight increase in creatinine clearance. It is not considered to
be due to renal impairment.14 We included elevated creatinine
as an ADR because the attending physicians were unaware of
this effect and altered the dose accordingly.
In the current study, we found that a higher daily dose of
> 16 mg/kg/d TMP/SMX was an independent factor for
cutaneous and other ADRs. Steroid use was not associated
with the occurrence of ADRs in our series.
The reason why higher daily doses of TMP/SMX are asso-
ciated with an increase in ADRs in patients with PJP and AIDS
remains unclear. High doses of TMP/SMXare known to produce
ADRs even in healthy individuals.1416 SMX are well-known to
produce skin eruptions. Some have postulated that TMP toxicity
is associated with glutathione deficiency,4,1720 altered levels of
thiols, disulfides, and plasma cysteine.21
We observed ADRs associated with increasing age and
greater TMP/SMX exposure. Previous studies have shown that
there are age-related changes of pharmacokinetics and
pharmacodynamics.2224 Age had a pharmacokinetic influ-
ence including absorption, distribution, metabolism, and
elimination influence, such as reduced renal and hepatic
clearance.2529 Because TMP/SMX is eliminated via the renal
system, it may be anticipated that renal dysfunction would
influence the pharmacokinetics and pharmacodynamics of
TMP/SMX with ageing.
The current study has several limitations. Firstly, it was a
retrospective study. The diagnosis of a TMP/SMX-related
ADR was determined by the attending physician rather than
an independent observer. Serum concentrations of TMP/SMX
were not measured. All the patients received a standard dose
of corticosteroids, which might have masked some of the
ADRs. It is difficult to compare our findings with those
of others because we included all potential ADRs while
others focused on skin eruptions or acute psychosis, and an
elevated serum creatinine does not necessarily reflect a
decrease in renal function. All of the adverse effects occurred
before Day 25 after TMP/SMX use for PJP and we did not
use prophylactic dose of TMP/SMX in our patients. Indeed,
the possibilities of antiretroviral therapy-related ADRs were
possible and difficult to differentiate with TMP/SMX related
ADRs in our study, even only a small proportion of patients
developed ADRs after 3 weeks of treatment. In addition, we
could not compare the different kinds of ADRS to the rele-
vance of high dose due to a relatively small sample size. The
strengths of this study include the relatively large number of
patients studied in a single institution over a 5-year period,
the use of actual body weight to assess the daily dose of
TMP/SMX, and inclusion of the virological and immuno-
logical markers of HIV infection. Prospective, protocol
guided studies, with independent observers are needed to
clarify these issues.
319H.-M. Chang et al. / Journal of the Chinese Medical Association 79 (2016) 314e319In conclusion, 40.3% of AIDS patients developed ADRs
while receiving TMP/SMX for PJP. Our findings indicate that
a daily dose of > 16 mg/kg of TMP/SMX with patients 
34 years of age increases the risk of ADRs. A large, well-
designed, prospective study is needed to confirm our findings.
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